Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - H.C. Wainwright raised its price target on CRISPR Therapeutics (NASDAQ:CRSP) to $80.00 from $65.00 on Thursday, while maintaining a Buy rating on the stock. The company, currently valued at approximately $5.1 billion, has seen its shares surge over 41% in the past six months. According to InvestingPro data, analyst targets for CRSP range from $32 to $268, reflecting diverse views on the company’s potential.
The increase follows CRISPR’s second-quarter 2025 financial results, which showed CASGEVY sales totaled $30 million, representing a 114% increase compared to first-quarter 2025 sales of $14 million. The company maintains a strong financial position, with more cash than debt on its balance sheet and a healthy current ratio of 16.6x. InvestingPro subscribers can access 12 additional key insights about CRISPR’s financial health and growth prospects.
CRISPR reported 16 patients were infused with CASGEVY in the second quarter, doubling from the eight infusions reported in the first quarter of 2025.
The firm noted this represents significant progress from previous quarters, with an estimated four patients infused in the fourth quarter of 2024 and one patient in the third quarter of 2024, based on reported CASGEVY revenues of $8 million and $2 million in those periods, respectively.
H.C. Wainwright updated its financial model to reflect the second-quarter 2025 results before raising its 12-month price target by $15.
In other recent news, CRISPR Therapeutics reported a significant earnings miss for the second quarter of 2025, with both earnings and revenue falling short of analyst expectations. The company posted a loss of $2.40 per share, which was substantially worse than the anticipated $1.40 per share. Revenue was reported at $890,000, far below the consensus estimate of $5.81 million. The disappointing financial results were largely attributed to higher-than-expected acquired in-process R&D expenses of $96.3 million, stemming from a recent agreement with Sirius Therapeutics. Additionally, Barclays (LON:BARC) raised its price target for CRISPR Therapeutics to $56 from $42, maintaining an Equalweight rating. This adjustment follows the company’s second-quarter earnings release and updates on its Casgevy treatment after Vertex Pharmaceuticals (NASDAQ:VRTX)’ earnings report. These developments highlight the ongoing challenges and strategic adjustments within CRISPR Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.